We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections

By LabMedica International staff writers
Posted on 07 May 2024

Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. More...

In the United States alone, approximately two million individuals are affected by sepsis annually, resulting in around 250,000 deaths. Similar statistics are reported in the European Union. Sepsis is characterized by life-threatening organ failure due to a dysfunctional systemic immune response. Rapid and accurate diagnostic methods are essential for timely and effective treatment, which is critical for patient survival. Now, a fully automated system for rapid antimicrobial susceptibility testing (AST) significantly reduces the time required to obtain clinically actionable results, thereby speeding up the administration of optimal treatments from days to just hours.

The ASTar System from Q-linea AB (Uppsala, Sweden) revolutionizes the treatment of sepsis by enabling a rapid therapeutic response directly from a positive blood culture in about six hours. This system equips physicians with the necessary tools to enhance patient outcomes and reduce mortality rates. The fully automated ASTar instrument ensures robust and consistent preparation of inoculums for AST, utilizing high-speed time-lapse microscopy to observe bacterial growth in broth, which helps determine the minimum inhibitory concentration (MIC). The ASTar system can be integrated with any rapid identification (ID) technology, enhancing laboratory capabilities and fulfilling the clinical demand for quicker diagnostic results.

The system includes an ASTar Consumable kit, which comprises two disposable components: a sample preparation Cartridge and an AST Disc. The Cartridge serves as a mini-lab, equipped with all necessary reagents and disposable items for sample preparation, concentration measurement, dilution, and growth medium adaptation. The AST Disc, used for AST and concentration determination, features over 330 culturing chambers pre-filled with antimicrobials at various concentrations, along with chambers for growth controls and bacterial concentration assessment for inoculum preparation. The ASTar system also combines high throughput with a user-friendly interface and simple load-and-go operation. Q-linea AB has recently received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for the ASTar System, which allows for its use in hospitals and laboratories across the United States.

“The approval is a significant step for Q-linea in the infectious disease diagnostics field in the U.S.,” said Stuart Gander, CEO of Q-linea. “Feedback from hospitals that have had early access to ASTar has been very positive, and we are excited to now be able to bring the system to labs across the U.S., which will make a real difference for patients with severe blood stream infections. We are pleased with the panel of drug-bug combinations which has been approved.”

Related Links:
Q-linea AB


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Rapid AKI Test
Acute Kidney Injury (AKI) Array (4-plex)
New
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.